I'm completely aware of the tissue-testing marketplace.
However, immunological vaccines is where most of the MONEY is going now and in the future. T-cell response testing can realistically only be done IN a fully functioning human body; not simply in surrogate tissue(s). (Not even on the famous "body on a chip.") Please do research before spouting ad hominem invectives.
Bioprinting has virtually nothing to do with curing cancer. They are two mutually exclusive market segments.
What are you trying to say?
Agreed. All I'm saying is that we won't see a huge movement in the stock price until one or more of these collaborations with BIG PHARMA is actually announced.
There is some promise here, but the video clip was somewhat underwhelming.
We need much more than University collaboration, though.
We need BIG PHARMA collaboration. That is what will really move a stock higher.
I'm not so sure you'll be saying that when we eventually get the 10-15% overall market correction early next year. Biotechs with no earnings are typically hit 2-3x as hard. Learn to take profits and re-invest wisely.
Get that stock certificate quick and put it in a safety deposit box before it's too late! Hurry! Time is of the essence!
Make sure that it's a legitimate stock certificate and not a fake.
There is a difference between being "long" in a stock like PG vs. being long in a stock like ONVO.
But you either believe in the value proposition or you don't. It certainly doesn't hurt to read news about any company, but watching the stock price closely on a daily basis means you're probably taking on too much risk for your type of investing.
He is a paid "sell-side" analyst, who apparently works for Jim Cramer and "The Street."
If you're long, you do NOT want him covering ONVO!
I couldn't agree more.
Without QE the DOW would still be around 10K instead of where it is today. Yellen will continue it for awhile, but there are some signs of tapering for next year.
A bigger issue may be the government budget, which needs to be "extended" again in January.
I know one thing. I'm taking profits the first week in January and riding out the impending correction from the sidelines. GLTA!
If you watch the stock on a daily basis, then you are not "truly long" then, are you?
Pieces of paper mean nothing. You're either long or you're not.
This is common with all start-ups which don't have any revenue yet, particularly in biotech. They have no "tangible" legs to stand on, as it where.
Until they start generating revenue, such small companies are open to blatant manipulation by hedge funds and the paid analysts who write articles under pseudonyms. It happens ALL of the time.
Watch out when Adam Feurstein covers this company!
Not one snippet of forward-looking "guidance" on revenue for 2014 and beyond. Only that the have little over $50M left from their original $100M to borrow.
This company has a great story, and a lot of potential, but much of it is years (if not decades) away. For example, they won't be able to bioprint a new heart for me in my lifetime.
The mindless hype surrounding this company is mind-blowing. LOL. I remain optimistic, but just not at the current valuation. We'll only be able to attribute some "real" value to the stock once forward-looking financial guidance is better defined.
In the meantime, it's a momentum trade only.
What I would have preferred to see is ACTUAL financial guidance for ONVO in those markets.
We've seen none of that for 2014 or beyond. Only that their first product will be ready by December (2014).